Evidence map›Paper›PMID 38360922›Full record

ArticleNature communications2024

Compact zinc finger architecture utilizing toxin-derived cytidine deaminases for highly efficient base editing in human cells.

Friedrich Fauser, Bhakti N Kadam, Sebastian Arangundy-Franklin, Jessica E Davis, Vishvesha Vaidya, Nicola J Schmidt, Garrett Lew, Danny F Xia, Rakshaa Mureli, Colman Ng and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Friedrich FauserSangamo Therapeutics, Inc., Brisbane, CA, USA.
Bhakti N KadamSangamo Therapeutics, Inc., Brisbane, CA, USA.
Sebastian Arangundy-FranklinSangamo Therapeutics, Inc., Brisbane, CA, USA.
Jessica E DavisSangamo Therapeutics, Inc., Brisbane, CA, USA.
Vishvesha VaidyaSangamo Therapeutics, Inc., Brisbane, CA, USA.
Nicola J SchmidtSangamo Therapeutics, Inc., Brisbane, CA, USA.
Garrett LewSangamo Therapeutics, Inc., Brisbane, CA, USA.
Danny F XiaSangamo Therapeutics, Inc., Brisbane, CA, USA.ORCID 0000-0003-3397-4787
Rakshaa MureliSangamo Therapeutics, Inc., Brisbane, CA, USA.
Colman NgSangamo Therapeutics, Inc., Brisbane, CA, USA.
Yuanyue ZhouSangamo Therapeutics, Inc., Brisbane, CA, USA.
Nicholas A ScarlottSangamo Therapeutics, Inc., Brisbane, CA, USA.ORCID 0000-0003-2827-6909
Jason EshlemanSangamo Therapeutics, Inc., Brisbane, CA, USA.
Yuri R BendañaSangamo Therapeutics, Inc., Brisbane, CA, USA.
David A ShivakSangamo Therapeutics, Inc., Brisbane, CA, USA.
Andreas ReikSangamo Therapeutics, Inc., Brisbane, CA, USA.
Patrick LiSangamo Therapeutics, Inc., Brisbane, CA, USA.
Gregory D DavisSangamo Therapeutics, Inc., Brisbane, CA, USA.
Jeffrey C MillerSangamo Therapeutics, Inc., Brisbane, CA, USA. jmiller@sangamo.com.ORCID 0009-0009-1637-262X
Sangamo BioSciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleobase editors represent an emerging technology that enables precise single-base edits to the genomes of eukaryotic cells. Most nucleobase editors use deaminase domains that act upon single-stranded DNA and require RNA-guided proteins such as Cas9 to unwind the DNA prior to editing. However, the most recent class of base editors utilizes a deaminase domain, DddA

Indexed as

Cytidine DeaminaseGene EditingCRISPR-Cas SystemsCytidineDNAHumansZinc FingersCytidineCytidine DeaminaseDNA

Identifiers

PMID38360922
PMCPMC10869815
OpenAlexW4391840604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.